The invention discloses a PCI postoperative MACE risk prediction marker for an acute
ST segment elevation type
myocardial infarction patient, and belongs to the field of biological
medicine. The application comprises application of a
reagent for detecting the
lipid metabolism marker in preparation of a kit for predicting the risk of main adverse cardiovascular events after the PCI operation of a patient suffering from the acute
ST segment elevation type
myocardial infarction, and the
reagent for detecting the
lipid metabolism marker comprises glycodeoxycholic acid, [(2R)-3-[(6Z, 9Z, 12Z)-octadeca-6, 9, 10-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, the detection
reagent is selected from one or more of a detection reagent for N-((2S, 3R)-1, 3-dihydroxy
octadecane-4-
alkene-2-yl)
acetamide, a detection reagent for 2-(2, 6, 7, 12-trienoyl) oxy-2-[(Z)-
octadecane-9-enoyl] oxypropyl] 2-(trimethyl
ammonium)
ethyl phosphate, 8-hydroxy-8-(3-octyl oxirane-2-yl) octanoic acid and N-((2S, 3R)-1, 3-dihydroxy
octadecane-4-
alkene-2-yl)
acetamide. The four
lipid metabolism markers (C44H80NO8P, C18H34O4, C20H39NO3 and C26H43NO5) screened by the invention are used for the prediction efficiency of MACE prediction, the sensitivity of the four lipid
metabolism markers reaches 0.889, the specificity of the four lipid
metabolism markers is 0.894, the AUC of the four lipid
metabolism markers is 0.921, and the four lipid metabolism markers have high sensitivity and high specificity.